LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Noninvasive fractional flow reserve measurement in stable CAD.

    Ouyang, H / Tonino, P A L

    Herz

    2013  Volume 40, Issue 3, Page(s) 452–453

    MeSH term(s) Cardiotonic Agents/therapeutic use ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/therapy ; Evidence-Based Medicine ; Fractional Flow Reserve, Myocardial ; Humans ; Percutaneous Coronary Intervention/methods ; Surgery, Computer-Assisted/methods
    Chemical Substances Cardiotonic Agents
    Language English
    Publishing date 2013-12-04
    Publishing country Germany
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 8262-4
    ISSN 1615-6692 ; 0340-9937 ; 0946-1299
    ISSN (online) 1615-6692
    ISSN 0340-9937 ; 0946-1299
    DOI 10.1007/s00059-013-4000-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1270: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 426: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Reply: To PMID 23588609.

    van Nunen, L X / Tonino, P A L

    Herz

    2015  Volume 40, Issue 3, Page(s) 453–454

    MeSH term(s) Cardiotonic Agents/therapeutic use ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/therapy ; Evidence-Based Medicine ; Fractional Flow Reserve, Myocardial ; Humans ; Percutaneous Coronary Intervention/methods ; Surgery, Computer-Assisted/methods
    Chemical Substances Cardiotonic Agents
    Language English
    Publishing date 2015-05
    Publishing country Germany
    Document type Comment ; Letter
    ZDB-ID 8262-4
    ISSN 1615-6692 ; 0340-9937 ; 0946-1299
    ISSN (online) 1615-6692
    ISSN 0340-9937 ; 0946-1299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1270: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 426: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Recent insights into the treatment of stable CAD : FFR-guided PCI vs. medical therapy.

    van Nunen, L X / Tonino, P A L

    Herz

    2013  Volume 38, Issue 4, Page(s) 376–381

    Abstract: Cornerstones in the treatment of coronary artery disease (CAD) are medical therapy and coronary revascularization. In acute settings (ST-elevation myocardial infarction and non-ST-elevation myocardial infarction), percutaneous coronary intervention (PCI) ...

    Abstract Cornerstones in the treatment of coronary artery disease (CAD) are medical therapy and coronary revascularization. In acute settings (ST-elevation myocardial infarction and non-ST-elevation myocardial infarction), percutaneous coronary intervention (PCI) has proven to improve prognosis. The optimal treatment of stable CAD is subject to great controversy. By using fractional flow reserve to guide PCI, it is possible to stent only those lesions that induce myocardial ischemia. This review aims to reflect on the use of FFR-guided PCI in stable CAD.
    MeSH term(s) Cardiotonic Agents/therapeutic use ; Combined Modality Therapy ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/therapy ; Evidence-Based Medicine ; Fractional Flow Reserve, Myocardial ; Humans ; Percutaneous Coronary Intervention/methods ; Surgery, Computer-Assisted/methods ; Treatment Outcome
    Chemical Substances Cardiotonic Agents
    Language English
    Publishing date 2013-04-17
    Publishing country Germany
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 8262-4
    ISSN 1615-6692 ; 0340-9937 ; 0946-1299
    ISSN (online) 1615-6692
    ISSN 0340-9937 ; 0946-1299
    DOI 10.1007/s00059-013-3806-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1270: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 426: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: The position of renal denervation in treatment of hypertension: an expert consensus statement.

    Zeijen, V J M / Kroon, A A / van den Born, B H / Blankestijn, P J / Meijvis, S C A / Nap, A / Lipsic, E / Elvan, A / Versmissen, J / van Geuns, R J / Voskuil, M / Tonino, P A L / Spiering, W / Deinum, J / Daemen, J

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

    2022  

    Abstract: Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients ...

    Abstract Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood pressure (BP) targets. In order to improve BP control and lower the risk of subsequent cardiovascular events, renal sympathetic denervation (RDN) has been introduced and studied as a non-pharmacological approach. While early data on the efficacy of RDN showed conflicting results, improvements in treatment protocols and study design resulted in robust new evidence supporting the potential of the technology to improve patient care in hypertensive subjects. Recently, 5 randomised sham-controlled trials demonstrated the safety and efficacy of the technology. Modelling studies have further shown that RDN is cost-effective in the Dutch healthcare setting. Given the undisputable disease burden along with the shortcomings of current therapeutic options, we postulate a new, clearly framed indication for RDN as an adjunct in the treatment of hypertension. The present consensus statement summarises current guideline-recommended BP targets, proposed workup and treatment for hypertension, and position of RDN for those patients with primary hypertension who do not meet guideline-recommended BP targets (see central illustration).
    Language English
    Publishing date 2022-08-24
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2211468-3
    ISSN 1876-6250 ; 1568-5888 ; 0929-7456
    ISSN (online) 1876-6250
    ISSN 1568-5888 ; 0929-7456
    DOI 10.1007/s12471-022-01717-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6216: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Indications for an early invasive strategy in NSTE-ACS patients.

    Zwart, B / Ten Berg, J M / van 't Hof, A W / Tonino, P A L / Appelman, Y / Liem, A H / Arslan, F / Waltenberger, J / Jukema, J W / de Winter, R J / Damman, P

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

    2019  Volume 28, Issue 3, Page(s) 131–135

    Abstract: An early invasive strategy in patients who have acute coronary syndrome without ST-elevation (NSTE-ACS) can improve clinical outcome in high-risk subgroups. According to the current guidelines of the European Society of Cardiology (ESC), the majority of ... ...

    Abstract An early invasive strategy in patients who have acute coronary syndrome without ST-elevation (NSTE-ACS) can improve clinical outcome in high-risk subgroups. According to the current guidelines of the European Society of Cardiology (ESC), the majority of NSTE-ACS patients are classified as "high-risk". We propose to prioritise patients with a global registry of acute coronary events (GRACE) risk score >140 over patients with isolated troponin rise or electrocardiographic changes and a GRACE risk score <140. We also acknowledge that same-day transfer for all patients at a high risk is not necessary in the Netherlands since the majority of Dutch cardiology departments are equipped with a catheterisation laboratory where diagnostic coronary angiography is routinely performed in NSTE-ACS patients. Therefore, same-day transfer should be restricted to true high-risk patients (in addition to those NSTE-ACS patients with very high-risk (VHR) criteria) in centres without coronary angiography capabilities.
    Language English
    Publishing date 2019-11-06
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2211468-3
    ISSN 1876-6250 ; 1568-5888 ; 0929-7456
    ISSN (online) 1876-6250
    ISSN 1568-5888 ; 0929-7456
    DOI 10.1007/s12471-019-01337-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6216: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.

    Deiman, B A L M / Tonino, P A L / Kouhestani, K / Schrover, C E M / Scharnhorst, V / Dekker, L R C / Pijls, N H J

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

    2016  Volume 24, Issue 10, Page(s) 589–599

    Abstract: Aim: This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost- ... ...

    Abstract Aim: This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost-effective.
    Methods and results: This single-centre, observational study included 3260 patients scheduled for elective PCI between October 2010 and June 2013 and followed for adverse cardiovascular events until October 2014. Post PCI, CYP2C19 poor metaboliser patients were treated with clopidogrel or prasugrel, in addition to aspirin. In total, 32 poor metabolisers were treated with clopidogrel and 41 with prasugrel. The number of adverse cardiovascular events, defined as death from cardiovascular cause, myocardial infarction, stent thrombosis, every second visit to the catheterisation room for re-PCI in the same artery, or stroke, within 1.5 years of PCI, was significantly higher in the CYP2C19 poor metaboliser group treated with clopidogrel (n = 10, 31 %) compared with the poor metaboliser group treated with prasugrel (n = 2, 5 %) (p = 0.003). Costs per gained quality-adjusted life years (QALY) were estimated, showing that genotype-guided post-PCI treatment with prasugrel could be cost-effective with less than € 10,000 per gained QALY.
    Conclusion: This study provides evidence that for CYP2C19-related poor metabolisers prasugrel may be more effective than clopidogrel to prevent major adverse cardiovascular events after PCI and this approach could be cost-effective.
    Language English
    Publishing date 2016-08-29
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2211468-3
    ISSN 1876-6250 ; 1568-5888 ; 0929-7456
    ISSN (online) 1876-6250
    ISSN 1568-5888 ; 0929-7456
    DOI 10.1007/s12471-016-0873-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6216: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Transcatheter aortic valve implantation amid the COVID-19 pandemic: a nationwide analysis of the first COVID-19 wave in the Netherlands.

    Rooijakkers, M J P / Li, W W L / Stens, N A / Vis, M M / Tonino, P A L / Timmers, L / Van Mieghem, N M / den Heijer, P / Kats, S / Stella, P R / Roolvink, V / van der Werf, H W / Stoel, M G / Schotborgh, C E / Amoroso, G / Porta, F / van der Kley, F / van Wely, M H / Gehlmann, H /
    van Garsse, L A F M / Geuzebroek, G S C / Verkroost, M W A / Mourisse, J M / Medendorp, N M / van Royen, N

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

    2022  Volume 30, Issue 11, Page(s) 503–509

    Abstract: Introduction: The coronavirus disease 2019 (COVID-19) pandemic has put tremendous pressure on healthcare systems. Most transcatheter aortic valve implantation (TAVI) centres have adopted different triage systems and procedural strategies to serve ... ...

    Abstract Introduction: The coronavirus disease 2019 (COVID-19) pandemic has put tremendous pressure on healthcare systems. Most transcatheter aortic valve implantation (TAVI) centres have adopted different triage systems and procedural strategies to serve highest-risk patients first and to minimise the burden on hospital logistics and personnel. We therefore assessed the impact of the COVID-19 pandemic on patient selection, type of anaesthesia and outcomes after TAVI.
    Methods: We used data from the Netherlands Heart Registration to examine all patients who underwent TAVI between March 2020 and July 2020 (COVID cohort), and between March 2019 and July 2019 (pre-COVID cohort). We compared patient characteristics, procedural characteristics and clinical outcomes.
    Results: We examined 2131 patients who underwent TAVI (1020 patients in COVID cohort, 1111 patients in pre-COVID cohort). EuroSCORE II was comparable between cohorts (COVID 4.5 ± 4.0 vs pre-COVID 4.6 ± 4.2, p = 0.356). The number of TAVI procedures under general anaesthesia was lower in the COVID cohort (35.2% vs 46.5%, p < 0.001). Incidences of stroke (COVID 2.7% vs pre-COVID 1.7%, p = 0.134), major vascular complications (2.3% vs 3.4%, p = 0.170) and permanent pacemaker implantation (10.0% vs 9.4%, p = 0.634) did not differ between cohorts. Thirty-day and 150-day mortality were comparable (2.8% vs 2.2%, p = 0.359 and 5.2% vs 5.2%, p = 0.993, respectively).
    Conclusions: During the COVID-19 pandemic, patient characteristics and outcomes after TAVI were not different than before the pandemic. This highlights the fact that TAVI procedures can be safely performed during the COVID-19 pandemic, without an increased risk of complications or mortality.
    Language English
    Publishing date 2022-06-01
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2211468-3
    ISSN 1876-6250 ; 1568-5888 ; 0929-7456
    ISSN (online) 1876-6250
    ISSN 1568-5888 ; 0929-7456
    DOI 10.1007/s12471-022-01704-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6216: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top